EML4 and non-small cell lung carcinoma: Here, we detected EGFR mutations using the amplification refractory mutation system (ARMS) in 721 NSCLC patients and measured EML4-ALK expression with the VENTANA ALK (D5F3) immunohistochemistry (IHC) method in 385 NSCLC patients to determine the feasibility of using small biopsy specimens for genetic testing and immunohistochemical detection.